Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium triple viable + Gegen Qinlian Tang
- Development stage
- Unknown
- Lead developer
- Jiangzhong Pharmaceutical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
This combination therapy consists of **Bifidobacterium Triple Viable Capsules** and the Traditional Chinese Medicine (TCM) decoction **Gegen Qinlian Tang**. The probiotic component typically contains live strains of *Bifidobacterium longum*, *Lactobacillus acidophilus*, and *Enterococcus faecalis*, which work to restore intestinal microflora balance and strengthen the mucosal barrier. Gegen Qinlian Tang is a classic herbal formula (comprising *Pueraria lobata*, *Scutellaria baicalensis*, *Coptis chinensis*, and *Glycyrrhiza uralensis*) known for its anti-inflammatory and anti-diarrheal properties. This combination is being investigated by **Jiujiang No.1 People's Hospital** for the prevention and treatment of acute radiation enteritis in patients undergoing abdominal or pelvic radiotherapy, aiming to mitigate intestinal injury and improve patient quality of life.
- Brand names
- Bifidobacterium Triple Viable Capsules
- Other names
- Gegen Qinlian Decoction + ProbioticsProbiotic Therapy With Gegen Qinlian Tang
Beyond the preview
Go deeper on bifidobacterium triple viable + Gegen Qinlian Tang.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium triple viable + Gegen Qinlian Tang.